Life and Times of Leading Cardiologists: Deepak Bhatt

This transcript has been edited for clarity.

E. Magnus Ohman, MD: Hello. I am Magnus Ohman, and I want to welcome you to another edition of Life and Times of Leading Cardiologists. We are very fortunate to have with us my old friend, Deepak Bhatt, who is professor of medicine at Harvard and head of the interventional program at Brigham.

You and I got together very early; I want to say in the '90s. We both learned a lot from working with Eric Topol and Rob Califf. We used to get together and have lunches at meetings, so this is almost like one of those lunches again.

Deepak L. Bhatt, MD, MPH: It brought back a lot of good memories when we were trying to figure out exactly when and where we met. Those were really great meetings. We got to know a lot of folks at Duke and Cleveland Clinic really well.

Ohman: Rob and Eric trained a lot of good people. Both of us trained with them, so we should be happy. Let's talk a little bit about your life. Where did you grow up, Deepak?

A Father's Academic Path

Bhatt: I consider you a good friend, and we have known each other really well for a long time, but you are right; we have never really talked about those sorts of things.

Authors and Disclosures

Authors

E. Magnus Ohman, MD

Professor of Medicine, Vice-Chair, Department of Medicine, Development & Innovation; Kent & Siri Rawson Director, Duke Program for Advanced Coronary Disease; Associate Director, Duke Heart Center, Duke University Medical Center, Durham, North Carolina

Disclosure: E. Magnus Ohman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, consultant, or trustee for: ABIOMED; 3D Communications; ACI Clinical; Biotie; Cara Therapeutics; Faculty Connection; Imbria; Janssen; Medscape; Milestone Pharmaceuticals; Xylocor
Received research grant from: ABIOMED; Chiesi; Portola
Received income in an amount equal to or greater than $250 from: ABIOMED; 3D Communications; ACI Clinical; Biotie; Cara Therapeutics; Cardinal Health; Faculty Connection; Imbria; Janssen; Medscape; Milestone Pharmaceuticals; Xylocor

Deepak L. Bhatt, MD, MPH

Professor of Medicine, Harvard Medical School; Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts

Disclosure: Deepak L. Bhatt, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as an advisor for: Cardax; Elsevier Practice Update Cardiology; Medscape Cardiology; PhaseBio; Regado Biosciences
Serve(d) on the board of directors for: Boston VA Research Institute; Society of Cardiovascular Patient Care
Serve(d) as the chair for: American Heart Association Quality Oversight Committee; Registry Steering Committee; VA Cart Research and Publivations Committee
Serve(d) on the data monitoring committee for: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute for the PORTICO trial, funded by ST. Jude Medical, now Abbott); Cleveland Clinic (including for the ExCEED trial, funded by Edwards); Duke Clinical Research Institute; Mayo Clinic; Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo); Population Health Research Institute
Received income in an amount equal to or greater than $250 from: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org, Vice Chair, ACC Accreditation Committee); Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim); Belvoir Publications (Editor-in-Chief, Harvard Heart Letter); Duke Clinical Research Institute; HMP Global (Editor-in-Chief, Journal of Invasive Cardiology); Journal of the American College of Cardiology (Guest Editor, Associate Editor); Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer); Slack Publications (chief Medical Editor, Cardiology Today's Intervention); Society of Cardiovascular Patient Care (Secretary/Treasurer); WebMD (CME steering committee)
Serve(d) as deputy editor for: Clinical Cardiology, NCDR-ACTION
Received research funding from: Abbott; Amarin; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chiesi; Eisai; Ethicon; Forest Laboratories; Idorsia; Ironwood; Ischemix; Eli Lilly; Medtronic; PhaseBio; Pfizer; Regeneron; Roche; sanofi aventis; Synaptic; The Medicines Company
Receives royalties for: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease) Site Co-Investigator for: Biotronik; Boston Scientific; St. Jude Medical (now Abbott); Svelte
Serve(d) as trustee for: American College of Cardiology